Curious to see your top suppliers emissions?
Book a demo for a pilot project
Book a demo for a pilot project
Wockhardt Limited, a prominent player in the global pharmaceutical industry, is headquartered in Mumbai, India. Founded in 1960, the company has established a strong presence in key operational regions, including the United States, Europe, and emerging markets. Wockhardt is renowned for its innovative approach to healthcare, focusing on biotechnology, generics, and specialty pharmaceuticals.
The company’s core products encompass a diverse range of therapeutic areas, including antibiotics, vaccines, and biopharmaceuticals, distinguished by their commitment to quality and research-driven development. Wockhardt has achieved notable milestones, such as receiving multiple FDA approvals and expanding its manufacturing capabilities across the globe. With a robust market position, Wockhardt continues to contribute significantly to the healthcare landscape, driven by its dedication to improving patient outcomes and advancing medical science.
-1 vs industry average
Wockhardt’s score of 39 is higher than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Scope 3 accounts for ••• of total emissions.
In 2025, Wockhardt reported total carbon emissions of approximately 69,000,000 kg CO2e, comprising 8,738,840 kg CO2e from Scope 1, 61,310,660 kg CO2e from Scope 2, and 9,019,110 kg CO2e from Scope 3. This data reflects a commitment to transparency in emissions reporting, with a focus on both direct and indirect emissions.
Wockhardt has set ambitious reduction targets, aiming for a 50% decrease in absolute emissions for both Scope 1 and Scope 2 by 2030, with the baseline year being 2021. This commitment underscores the company's proactive approach to climate action and aligns with industry standards for sustainability.
The emissions data is not cascaded from any parent organization, indicating that Wockhardt Limited independently reports its carbon footprint. The company continues to enhance its environmental strategies, contributing to a more sustainable future in the pharmaceutical industry.
Access structured emission data, company specific factors and auditable source documents
2025
Near-zero scope 1 & 2
Target to achieve near-zero emissions for direct operations and purchased energy
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
No scope 3 category breakdown has been disclosed yet.


You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more